A combined treatment of β-elemene and cetuximab induces KRAS mutant CRC cell ferroptosis via the downregulation of GPX4 and SLC7A11 [91], and the inhibition of SLC7A11 induces the ferroptosis of CRC stem cells [92]. The gene discussed is GPX4; the disease is colorectal carcinoma.